Navigation Links
Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC
Date:7/15/2008

BOSTON, July 15 /PRNewswire/ --Scimitar Equity, LLC issues a review of Advaxis, Inc (OTC Bulletin Board: ADXS), entitled, "The New Generation of Cancer Immunotherapeutics".

This review is available at website: http://www.scimitarequity.com.

Based in North Brunswick, New Jersey, Advaxis, Inc is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania and Chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets HPV-associated cancers such as cervical and head and neck. Current Lm vaccines in development target prostate, breast, ovarian and other cancers. Recently, Advaxis completed a Phase I clinical trial of Lovaxin C. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia ("CIN"). The Lm platform also has applications in the fields of infectious disease and autoimmune disorders. For further information, please visit: http://www.advaxis.com .

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about Advaxis, Inc (OTCBB: ADXS) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that
'/>"/>

SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
4. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... DIEGO , March 31, 2015 Neurocrine ... it has entered into an exclusive collaboration and licensing ... inhibitor, NBI-98854, in Japan and ... (TSE: 4508). Mitsubishi Tanabe intends to initially develop NBI-98854 ... associated with Huntington,s disease and tardive dyskinesia. Neurocrine retains ...
(Date:3/31/2015)... , March 31, 2015 UHC has ... the use of medical devices based on cost and ... physician preference items (PPIs). The study examined utilization of ... hospital,s supply expenses 1 —at 10 academic medical centers, ... stents, and cardiac valves. The study, ...
(Date:3/31/2015)... and ORANGEBURG, N.Y., March 31, 2015 /PRNewswire/ ...  VSCI) today announced the completion of their merger. ... and completion of the all-stock combination creates a ... Beginning on April 1, 2015, Cogentix Medical, Inc. ... CGNT. Cogentix Medical will have its U.S. headquarters ...
Breaking Medicine Technology:Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4
... Data,presented at the 2007 Annual Scientific Meeting of ... alli(R) (orlistat 60mg), the,only FDA- approved, over-the-counter (OTC) ... in helping them lose weight, and,not to potential ... data show that the weight loss achieved with ...
... Sanofi-aventis announced today,that the Japanese Ministry of ... for a Supplemental New Drug Application (sNDA) ... angina pectoris, non-ST elevation,myocardial infarction) for which ... Plavix(R) (clopidogrel). Approximately 100,000 patients develop ...
Cached Medicine Technology:Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects 2Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 2Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 4Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 5
(Date:4/1/2015)... (PRWEB) April 01, 2015 Nike Golf ... Development Camps in Arizona and Florida. These programs are ... lower their score in a golf-intensive environment and to ... led by University of Arizona coaching legend, Rick LaRose, ... on the knowledge gaps as it pertains to the ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Enterprise ... 501 Global Edition, a distinguished list and report ... (MSPs). The complete 501 list is currently available ... ,     The top ranked MSPs in North America ... East and Africa ,     The top MSPs ...
(Date:3/31/2015)... Every day a new diet fad is introduced in ... in other countries, and the diagnosis of American's with ... Natural Health Centers believe that by educating not only ... the future development of obesity and many other debilitating ... at no charge in their clinics. Because yo-yo and ...
(Date:3/31/2015)... Los Angeles, CA (PRWEB) March 31, 2015 ... the robotic hair transplant technique have yielded ... manual method , when refined and perfected by a ... results. While the most advanced techniques of hair restoration ... manual techniques can still be used to add precision ...
(Date:3/31/2015)... In conjunction with the Asbestos Awareness ... Mesothelioma Applied Research Foundation (Meso Foundation) announced the ... its existing work in mesothelioma research, education, support, ... Meso Foundation’s mission, we want to eliminate harmful ... asbestos, including mesothelioma,” said the Meso Foundation’s executive ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 2Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 3Health News:Beverly Hills Hair Transplant Surgeon Now Combines Advanced Robotic Hair Transplantation and Manual Techniques for Greatest Results 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3
... , , , , ... Field of Green Chemistry September 15 at UC Berkeley Campus ... Consumer concerns over hazardous chemicals in the air and water have ... chemistry. "The most troubling health effects are associated with endocrine disrupting ...
... will respond to cancer drug , TUESDAY, Sept. 8 (HealthDay ... certain aggressive cancers -- including those that attack the pancreas, ... drug. , The key appears to lie in a molecular ... issue of Nature Medicine . , Researchers at the ...
... agent lapatinib to delay tumor growth and improve the ... cancer, only benefited certain subgroups of patients. While results ... toxicity from the drug in the form of a ... and longer survival. Findings of this phase ...
... By investigating a rare and severe form of diabetes ... new molecular mechanism that regulates specialized pancreatic cells and ... which UI researchers previously linked to potentially fatal human ... this week in the Early Edition of the ...
... awarded a consortium of Chicago-based institutions, led by Rush ... a Developmental Center for AIDS Research, creating a comprehensive ... translational research in the prevention, detection and treatment of ... one of only two in the Midwest the ...
... MINNEAPOLIS/ST. PAUL (September 8, 2009)The Center for Infectious ... of Minnesota is convening an international summit on ... The summit will give business and health ... to protect employee health, critical operations and customer ...
Cached Medicine News:Health News:Inventor of Green Catalysts Offers Solutions for Cleaning Toxins and Pollutants in the Environment 2Health News:Lapatinib shows minimal effect against liver cancer 2Health News:Lapatinib shows minimal effect against liver cancer 3Health News:Team reveals molecular mechanism underlying a form of diabetes 2Health News:NIH awards major grant to Chicago-based consortium to create center for AIDS research 2Health News:NIH awards major grant to Chicago-based consortium to create center for AIDS research 3Health News:U of M convenes a summit on the H1N1 influenza pandemic and critical business preparedness 2
... Projector Chart w/ Remote/Controller. Includes ... Adults & Children. Multiple 20/20 slides. ... Programmable feature allows you to customize your ... Halogen Illumination with Long Life. Variety of ...
... The Ultimate in ... Octopus 4.3 stabilizer features ... unmatched stability in the ... 4.3 Stabilizer features the ...
... Inc., the leader in beating heart bypass, ... new Starfish NS device is the first ... patient acceptance of surgical revascularization.,The Starfish NS ... the Multi-Vessel Small Thoracotomy (MVST) procedure without ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
Medicine Products: